Fluidigm Buys DVS for $207.5 Million
Fluidigm stated that the acquisition enlarges its presence in the cell biology market. DVS’s sales for the first nine months of 2013 grew 123.0% to $18.5 million and net income totaled $1.5 million, according to an SEC filing. Fluidigm’s goal for DVS revenue growth in 2014 is 23%–28%. At the end of 2013, DVS had an installed base of 70 instruments. Technology for the ICP-TOF MS–based CyTOF, which costs $630,000, is licensed from PerkinElmer.
South San Francisco and Sunnyvale, CA 1/29/14—Fluidigm has definitely agreed to acquire DVS Sciences, a provider of multiparameter single-cell protein analysis systems, for $207.5 million in stock and cash. DVS’s mass cytometry technology includes the CyTOF 2 Mass Cytometer, which analyzers antibody/metal complexes using atomic MS. “We believe the acquisition of DVS will increase Fluidigm’s single-cell revenue immediately, as well as increase our addressable market to include the approximately $300 million high-end research flow cytometry segment. It also expands our analytical breadth to include single-cell protein analysis,” commented Fluidigm President and CEO Gajus Worthington. Several members of DVS management will join Fluidigm, including cofounder and CTO Dr. Scott Tanner. The transaction is expected to close next month.
